NCT03217617View on ClinicalTrials.gov

SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
SCID, X-Linked
Interventions
BIOLOGICAL

Direct intravenous injection of ivlv-X1 lentiviral vector

ivlv-X1 LV intravenous injection at a dose of \~1x10e9/kg body weight.

Trial Locations (2)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

Unknown

RECRUITING

Guilin Hospital of Chinese Traditional and Western Medicine, Guilin

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER